Mer­ck scores an­oth­er win for King Keytru­da, this time in HER2-neg­a­tive can­cer

Mer­ck’s an­ti-PD1 on­col­o­gy megablock­buster Keytru­da is plan­ning on adding an­oth­er in­di­ca­tion to its ar­ray, tout­ing a Phase III win in its march to reg­u­la­tors. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER